Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista de Neuro-Psiquiatría
versión impresa ISSN 0034-8597
Resumen
CALDERA, David J y BURNEO, Jorge G. Juvenile myoclonic epilepsy. Rev Neuropsiquiatr [online]. 2018, vol.81, n.4, pp.250-256. ISSN 0034-8597. http://dx.doi.org/10.20453/rnp.v81i4.3439.
Juvenile Myoclonic Epilepsy (JME) is a generalized type of epilepsy characterized by the occurrence of myoclonic seizures and, less frequently, of generalized tonic-clonic seizures and absences. The onset usually occurs during puberty or adolescence. Worldwide, it is estimated that there is a new case of JME per year for every 1000-2000 people. Its diagnosis is fundamentally clinical, corroborated by EEG tests. The first drug of choice for the treatment of JME is still valproic acid; however, lamotrigine and levetiracetam have shown efficacious results for the control of JME, used as monotherapy or polytherapy with topiramate as a coadyuvant for the control of generalized tonic- clinic seizure.
Palabras clave : Epilepsy; juvenile; myoclonic epilepsy; myoclonus; JME.